The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc. (ALT) Shareholders

Core Viewpoint - Altimmune, Inc. is facing a class action lawsuit following the announcement of disappointing results from its IMPACT Phase 2b MASH trial, which led to a significant drop in its stock price [3][4]. Group 1: Company Overview - Altimmune, Inc. is a biopharmaceutical company involved in the development of treatments for liver diseases, specifically focusing on MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) [3]. - The company reported topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which did not meet the expected statistical significance for its primary endpoint related to fibrosis reduction [3]. Group 2: Stock Performance - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price plummeted from $7.71 per share to $3.61 per share, marking a decline of 53.2% in just one day [3]. Group 3: Legal Proceedings - Shareholders who purchased shares of Altimmune during the class period from August 10, 2023, to June 25, 2025, are encouraged to register for participation in the class action lawsuit [4]. - The deadline for shareholders to seek lead plaintiff status is October 6, 2025 [4].